Ionis Pharmaceuticals (IONS) Assets Average (2010 - 2026)

Ionis Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $3.5 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 19.89% year-over-year to $3.5 billion in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 19.89% increase from a year earlier, with the FY2025 full-year figure at $3.3 billion, up 8.91% from the prior year.
• Assets Average rose to $3.5 billion in Q1 2026 per IONS's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Assets Average topped out at $3.5 billion in Q1 2026 and bottomed at $2.4 billion in Q3 2022.
• The 5-year median for Assets Average is $2.9 billion (2025), against an average of $2.9 billion.
• Across the five-year window, Assets Average grew 21.05% in 2023 and dropped 6.85% in 2024, its largest moves.
• Year by year, Assets Average stood at $2.5 billion in 2022, then gained by 19.54% to $3.0 billion in 2023, then gained by 2.71% to $3.0 billion in 2024, then advanced by 7.76% to $3.3 billion in 2025, then rose by 6.36% to $3.5 billion in 2026.
• Per Business Quant, the three latest IONS Assets Average figures stand at $3.5 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.0 billion (Q3 2025).